BRTX - BioRestorative Therapies, Inc.
After hours:
Chart Events
MACD
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 5.74 |
| Open | 5.83 |
| Bid | 5.20 x 800 |
| Ask | 5.75 x 800 |
| Day's Range | 5.12 - 5.83 |
| 52 Week Range | 2.46 - 6.33 |
| Volume | |
| Avg. Volume | 600,158 |
| Market Cap | 20.216M |
| Beta (5Y Monthly) | 61.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.70 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.50 |
Fair Value
Related Research
BenzingaEXCLUSIVE: BioRestorative Therapies Wins License from New York State Department of Health To Act As Tissue Bank for Mesenchymal Stem Cell Processing
BioRestorative Therapies, Inc (NASDAQ: BRTX), bagged a license from the New York State Department of Health to act as a tissue bank for processing mesenchymal stem cells from autologous donors. What Happened? Licensure is an intensive and diligent process for all tissue and cell-related activities in New York, including collection, processing, storage, and distribution, and any facility distributing tissues to other states. Holders of a New York State license must comply with regulations to ensu
GlobeNewswireBioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing
--License will enable expanded clinical operations for investigator-initiated trials and potential “right to try” uses of BRTX-100.— MELVILLE, N.Y., May 31, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has received a license from the New York State Department of Health to act as a tissue bank for the processing of mesenchymal stem cells from
BenzingaEXCLUSIVE: BioRestorative Therapies' ThermoStem For Metabolic Disorders Expected To Receive Fourth Japanese Patent
BioRestorative Therapies Inc (NASDAQ: BRTX) has announced that the Japanese Patent and Trademark Office has issued a notice of allowance for a patent application related to its metabolic ThermoStem program. What Happened: The notice of allowance was issued on May 8, 2023. Upon issuance, this will be the fourth patent granted in Japan for the ThermoStem program. The new Japanese patent will cover implantable three-dimensional scaffolds and brown adipocytes derived from human brown adipose (fat)-d
- GlobeNewswire
BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
--Upon issuance, patent will be the fourth Japanese patent to issue for the ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the Japanese Patent and Trademark Office has issued a notice of allowance for a patent application related to
ACCESSWIREA New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market
Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike.
- GlobeNewswire
BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial
New York State’s largest health care provider will participate in BRTX’s clinical trial Expansive universe of patients and clinical sites from which to recruit high quality subjectsLeverage Northwell’s “Center for Regenerative Orthopedic Medicine”Potential future collaborations to be explored in connection with basic science research MELVILLE, N.Y., May 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage comp
- GlobeNewswire
BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City
MELVILLE, NY., May 04, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Inaugural EF Hutton Global Conference taking place May 10th to 11th at the Plaza Hotel in New York City. The Inaugural EF Hutton Global Conference is a two-day, invitation-only event featuring key executives from approximately 150 public and p
BenzingaEXCLUSIVE: BioRestorative Concludes Enrollment For Safety Run-In Component Of Cell Therapy Study For Chronic Lower Back Pain
BioRestorative Therapies Inc (NASDAQ: BRTX) has completed enrollment for the safety run-in component of its Phase 2 study of BRTX-100 targeting patients suffering from chronic lumbar disc disease (cLDD). What Happened: BRTX-100 is the company's lead clinical candidate, a cell-based therapeutic engineered to target areas of the body with little blood flow. BRTX-100 is currently in a Phase 2 trial for cLDD to evaluate the safety and preliminary efficacy of a single dose of BRTX-100. Ninety-nine el
- GlobeNewswire
BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100
--Clinical data from safety run-in scheduled to be released in second half of 2023.— MELVILLE, N.Y., April 24, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has completed enrollment for the safety run-in component of its Phase 2 clinical study of BRTX-100 targeting patients suffering from chronic lumbar disc disease (cLDD). BRTX-100 is the Co
News DirectBioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion
By Julian Richard, Benzinga
Simply Wall St.Bullish BioRestorative Therapies, Inc. (NASDAQ:BRTX) insiders filled their treasuries with US$593k worth of stock over last year
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
News DirectWhat Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
By Julian Richard, Benzinga
BenzingaEXCLUSIVE: BioRestorative Seeks Expanded FDA Approval For BRTX-100 Clinical Application, Engages Advisory Firm
BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into an agreement with Bruder Consulting & Venture Group, a full-service strategic advisory, to assist the company in seeking FDA approval for the expanded clinical application of BRTX-100. BRTX-100 is BioRestorative's lead clinical candidate, a novel cell-based therapeutic engineered to target areas of the body with little blood flow. BRTX-100 is currently being evaluated in connection with a Phase 2 clinical trial in chronic lumbar disc d
- GlobeNewswire
BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100
Bruder Consulting & Venture Group engaged to expand BRTX-100 clinical indication pipeline MELVILLE, N.Y., March 13, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has entered into an agreement with the Bruder Consulting & Venture Group (“BCVG”), a full service strategic advisory firm with focus areas in biologics, tissue repair, biomaterials a
News DirectBRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
By Julian Richard, Benzinga
- GlobeNewswire
BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023
Melville, NY., March 07, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate at the Roth 35th Annual Conference being held from March 12 – 14 at The Ritz Carlton, Laguna Niguel in Dana Point, California. Lance Alstodt, President and CEO of the Company, will be available for one-on-ones at the conference and wi
BenzingaEXCLUSIVE: BioRestorative To Receive Third US Patent For Metabolic ThermoStem Program
The United States Patent and Trademark Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program. What Happened: This will be the third patent granted under this family of intellectual property claims under the new patent covering implantable three-dimensional scaffolds and brown adipocytes derived from human brown adipose-derived stem cells. Last month, the European Patent Office issued a notice of allo
- GlobeNewswire
BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
--Notice of allowance will be the third US patent to issue from this ThermoStem® family targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to t
News DirectBioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
By Julian Richard, Benzinga
- GlobeNewswire
BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program
--Patent provides protection in key international markets for BioRestorative’s ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has issued a notice of allowance for a patent application related to the Compan
BenzingaEXCLUSIVE: BioRestorative Poised To Receive European Patent For ThermoStem Program
The European Patent Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program. The notice of allowance was issued on February 6, 2023. What Happened: Claims granted under the new patent cover implantable three-dimensional scaffolds and brown adipocytes derived from human brown adipose-derived stem cells. Related: EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Synd
News DirectBioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
By Julian Richard, Benzinga
News Direct2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
By Faith Ashmore, Benzinga
- Newsfile
BioRestorative Therapies to Present in The Jan 26th Virtual Investor Summit Microcap Event
Melville, New York--(Newsfile Corp. - January 17, 2023) - BioRestorative Therapies (NASDAQ: BRTX) ("BioRestorative", "BRTX" or the "Company"), a clinical stage company focused on stem cell-based therapies, announced today that management will be presenting at the virtual Investor Summit. During the presentation, BioRestorative Therapies Chief Executive Officer, Lance Alstdot, will highlight the Company's regenerative medicine platform and technology. The company is currently engaged in a Phase 2
- GlobeNewswire
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
--Non-Dilutive Grant Funding to Support Development of Brown Adipose-Based Therapeutic Programs Directed at Polycystic Ovary Syndrome -- MELVILLE, N.Y., Dec. 06, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child H